Health Technology Assessment (HTA)

Health technology assessment (HTA) is the systematic, multidisciplinary process by which a national or regional body evaluates a health technology — a drug, a medical device, a diagnostic test, or a clinical procedure — to inform a coverage, pricing, or reimbursement decision. The World Health Organization, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and Health Technology Assessment international (HTAi) converge on essentially the same definition: HTA uses explicit, structured methods to determine a technology’s value across several dimensions at once, not clinical effectiveness alone. HTA names the general discipline and its worldwide family of bodies; a specific national process — most visibly, NICE’s technology appraisal in the UK, covered in depth in CASRAI’s NICE technology appraisal process guide — is one implementation of it, not a synonym for it.

What an HTA evaluates

A full health technology assessment is built to look beyond whether a technology simply works, covering:

• Clinical effectiveness. Whether the technology performs better than existing alternatives, drawn from trial and real-world evidence.
• Cost-effectiveness. Whether the health gain justifies the cost, assessed through cost-effectiveness analysis or, more specifically, cost-utility analysis expressed as an ICER in cost per QALY gained.
• Safety. Adverse-event and risk evidence, alongside effectiveness data.
• Broader social, ethical, and organisational impact. How the technology affects patient quality of life, health equity, and how a health system would need to change to deliver it — the dimension that most clearly separates HTA from a narrower regulatory approval decision.

HTA bodies around the world

HTA is performed by a genuine international family of institutions, each with its own process, evidence requirements, and cost-effectiveness threshold, evaluating largely the same kind of evidence for the same underlying purpose — a reimbursement or coverage decision:

• NICE (National Institute for Health and Care Excellence, UK) — runs technology appraisal, covered in CASRAI’s dedicated guide.
• IQWiG (Institute for Quality and Efficiency in Health Care, Germany).
• HAS (Haute Autorité de Santé, France).
• CADTH (Canada’s Drug Agency, formerly the Canadian Agency for Drugs and Technologies in Health).
• PBAC (Pharmaceutical Benefits Advisory Committee, Australia).
• ICER (Institute for Clinical and Economic Review, US) — a nonprofit performing HTA-style assessment in a US market that otherwise has no single statutory HTA body; note the acronym collision with the incremental cost-effectiveness ratio, a completely different, numeric concept covered in CASRAI’s ICER dictionary entry.

Why this distinction matters for a research or submissions team

A clinical trial or economic-evaluation team preparing evidence for reimbursement needs to know which specific HTA body it is submitting to, because the underlying discipline — HTA in general — sets the shared vocabulary (clinical effectiveness, cost-effectiveness, an ICER weighed against a threshold) while each body’s own process sets the actual deadlines, evidence templates, and committee structure the submission has to satisfy. CASRAI’s CHEERS 2022 checklist guide covers the current standard for reporting the underlying economic evaluation regardless of which specific HTA body ultimately receives it.

Frequently asked questions

Is HTA the same thing as drug regulatory approval?

No. Regulatory approval (by the FDA, MHRA, or EMA) determines whether a technology is safe and effective enough to be sold at all. HTA is a separate, usually later step that determines whether a health system should pay for it, at what price, and for which patients — a technology can be fully approved and still receive a negative HTA recommendation on cost-effectiveness grounds.

Does every country have an HTA body?

Most high-income health systems with centralised public payers do (NICE, IQWiG, HAS, CADTH, PBAC among them). The US does not have one single statutory HTA body for its overall health system, though the nonprofit ICER performs an HTA-style function, and the Medicare program now runs its own value-assessment process for a defined set of drugs under the Inflation Reduction Act.

How does HTA relate to a NICE technology appraisal specifically?

A NICE technology appraisal is one country’s specific HTA procedure — CASRAI’s NICE technology appraisal process guide covers its single technology appraisal (STA) and multiple technology appraisal (MTA) routes, its Evidence Review Group and appraisal committee structure, and how it applies a cost-effectiveness threshold to the submitted ICER in detail this general entry does not repeat.